Parexel Int'l (PRXL) shares were up more than 7% Monday afternoon after the Wall Street Journal reported that the company has partnered with investment banks and is seeking a sale.
Parexel is a contract research organization that partners with drug companies to conduct clinical trials. Parexel has a market cap of about $3.5 billion and could fetch a price of about $4 billion, according to the Journal.
Parexel has received interest from a group of activist investors, including Corvex Management which already has a large stake in the company.
Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get hisinsights or analysis with a free trial subscription to Real Money.